Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Aug 4:17:2401-2412.
doi: 10.2147/IJWH.S530879. eCollection 2025.

Hysteroscopic Myomectomy for Type 2 Submucosal Myoma Pretreated by HIFU and Mifepristone Treatment: A Case Report and Literature Review

Junjie Li #  1   2 , Leilei Yang #  2 , Yan Wang  2 , Min He  3 , Hongqiu Zhu  2 , Yefang Huang  2
Affiliations
Case Reports

Hysteroscopic Myomectomy for Type 2 Submucosal Myoma Pretreated by HIFU and Mifepristone Treatment: A Case Report and Literature Review

Junjie Li et al. Int J Womens Health. .

Abstract

Hysteroscopic myomectomy is the first-line treatment for the removal of submucosal myoma in women facing fertility requirements. However, in the face of large diameter type 2 submucosal myoma, patients are at greater risk of complications such as uterine perforation and fluid overload during hysteroscopy. When the diameter of type 2 submucous myoma is greater than 4cm, the three-phase treatment of high intensity focused ultrasound (HIFU), drugs and hysteroscopy is effective and safe. We shared a case of a 30-year-old non-pregnant woman, who had a history of uterine submucous myoma for more than 4 years with symptoms of heavy menstruation, prolonged menstruation and secondary severe anemia. The patient's initial pelvic magnetic resonance results suggested a type 2 uterine submucous myoma with a diameter of more than 4cm. We first performed HIFU on the patient, followed by the patient's oral intake of mifepristone tablets for 3 months, and prior to hysteroscopic surgery, the patient's fibroid type was shifted to type 0, and finally successfully completed hysteroscopic myomectomy (HM). Finally, we conclude that when the diameter of type 2 submucosal myoma exceeds 4 cm, preoperative application of HIFU combined with drug treatment should be considered to maximize the reduction of fibroids, improve symptoms such as anemia and dysmenorrhea, reduce the time required for hysteroscopic surgery, and improve the safety of surgery.

Keywords: high intensity focused ultrasound; hysteroscopic myomectomy; mifepristone; submucous myoma of uterus; uterine fibroid.

PubMed Disclaimer

Conflict of interest statement

Junjie Li is now affiliated with Traditional Chinese Medicine Department, Hunan University of Medicine General Hospital, Hunan, Huaihua, 418000, People’s Republic of China. All authors declare that there is no conflict of interest in this study.

Figures

Figure 1
Figure 1
Magnetic resonance imaging of the largest myoma in the uterine cavity before HIFU treatment (A and B). Magnetic resonance imaging of the largest myoma in the uterine cavity after contrast enhancement (C and D).
Figure 2
Figure 2
Magnetic resonance imaging of uterus after HIFU treatment (A,C and E). Uterine magnetic resonance imaging after contrast enhancement (B,D and F). The picture shows that uterine myoma is located in the cervical canal.
Figure 3
Figure 3
Ultrasound scan results of the uterus after one month of mifepristone treatment (A and B). The ultrasound scan results of the uterus after two months of mifepristone treatment (C, E). Ultrasound scan results of the uterus after three months of mifepristone treatment (D). The “M” in the Figure 3 represents a leiomyoma. According to the ultrasound results, the majority of the patient’s submucosal myoma was located in the uterine cavity, and it was considered to be converted to type 0.
Figure 4
Figure 4
(A–D) Submucosal myoma removed in the uterine cavity during hysteroscopy. Immunohistochemical staining showed that Ki-67, er, SMA and demsin were positive, while CD34 and CD10 were negative.
Figure 5
Figure 5
Two months after the completion of all treatments, the patient’s ultrasound results showed complete removal of submucosal myoma. The “M” in the Figure 5 represents a leiomyoma.
See this image and copyright information in PMC

References

    1. American Association of Gynecologic Laparoscopists (AAGL): Advancing Inimally Invasive Gynecology Worldwide. AAGL practice report: practice guidelines for the diagnosis and management of submucous leiomyomas. J Minim Invasive Gynecol. 2012;19(2):152–171. doi: 10.1016/j.jmig.2011.09.005 - DOI - PubMed
    1. Bonafede MM, Pohlman SK, Miller JD, et al. Women with newly diagnosed uterine fibroids: treatment patterns and cost comparison for select treatment options. Popul Health Manag. 2018;21(S1):S13–S20. doi: 10.1089/pop.2017.0151 - DOI - PubMed
    1. Soliman AM, Yang H, Du EX, et al. The direct and indirect costs of uterine fibroid tumors: a systematic review of the literature between 2000 and 2013. Am J Obstet Gynecol. 2015;213(2):141–160. doi: 10.1016/j.ajog.2015.03.019 - DOI - PubMed
    1. Chabbert-Buffet N, Esber N, Bouchard P. Fibroid growth and medical options for treatment. Fertil Steril. 2014;102(3):630–639. doi: 10.1016/j.fertnstert.2014.07.1238 - DOI - PubMed
    1. Munro MG, Critchley HOD, Fraser IS. FIGO menstrual disorders committee. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions [published correction appears in Int J Gynaecol Obstet. 2019 Feb;144(2):237]. Int J Gynaecol Obstet. 2018;143(3):393–408. doi: 10.1002/ijgo.12666 - DOI - PubMed

Publication types

LinkOut - more resources